doi.org/10.1016/j.annonc.2022.09.159

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

..., Eun Kyung Cho
36
Annals of Oncology65.40
Volume: 33, Issue: 12, Pages: 1250 - 1268
Published: Oct 10, 2022
Paper Fields
Paper Details
Title
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
DOI
doi.org/10.1016/j.annonc.2022.09.159
Published Date
Oct 10, 2022
Journal
Annals of Oncology
Volume
33
Issue
12
Pages
1250 - 1268
© 2025 Pluto Labs All rights reserved.